| 第 48 卷第 4 期 |  | Vol. 48 No. 4 | | 2018 年 8 月 | Aug 2018 |
|
所屬欄目：專(zhuān)論與綜述
ALK抑制劑上市藥物的研發(fā)歷程 |
| 張溢凡
（中國人民解放軍93575部隊衛生隊，河北 承德 067000） |
| 摘 要：ALK為間變性淋巴瘤激酶，是胰島素受體酪氨酸激酶家族中的一員。ALK基因在多種腫瘤細胞中異�；钴S，是抗腫瘤藥物研究中較為成熟的重要靶標之一。主要對ALK的結構與功能、EML4-ALK融合基因信號通路在治療NSCLC中的調控作用以及目前已經(jīng)上市的ALK抑制劑的研發(fā)歷程進(jìn)行綜述，旨在為藥物，特別是以ALK為靶點(diǎn)的藥物研發(fā)提供指導。 |
| 關(guān)鍵詞：ALK抑制劑；EML4-ALK融合基因；非小細胞肺癌（NSCLC） |
| 中圖分類(lèi)號：R971 文獻標識碼：B 文章編號：1009-9212（2018）04-0008-08 |
|
| Development History of Marketed ALK Inhibitors |
| ZHANG Yi-fan
(Health Unit of 93575 Troop, the People's Liberation Army of China, Chengde 067000, China) |
| Abstract：ALK, an anaplastic lymphoma kinase, is a member of the insulin receptor tyrosine kinase family. It was observed that the ALK gene was extremely active in a variety of tumor cells and was an important target for the study of antitumor drugs. This review mainly discussed the structure and function of ALK, and the role of the EML4-ALK mutations signaling pathway in treating NSCLC. Meanwhile, the development process of currently marketed ALK inhibitors was also described focusing on providing effective research ideas for developing new drugs based on ALK or other targets. |
| Key words：ALK inhibitor; EML4-ALK mutations; non-small cell lung cancer (NSCLC) |
|
作者簡(jiǎn)介：張溢凡（1991-），男，河南鄭州人，藥師，主要從事生物技術(shù)研究（E-mail：149889071@qq.com）。
|
收稿日期： 2018-06-2
|
|